Nobel Prize-Inspired Breakthrough: Bodic Health and RuiPu Bio Launch World’s First Treg-Mechanism Drug, Pioneering a New Path in Immune Therapy

On October 27, 2025, just as the 2025 Nobel Prize in Physiology or Medicine (recognizing the discovery of the regulatory T cell/Treg peripheral immune tolerance mechanism) had been announced,Benerhera (Shaoxing) Biotechnology Co., Ltd.(hereinafter referred to as"Benerhera") with the leading company in China's animal health fieldRipbio Biological Co., Ltd.(hereinafter referred to as"Rep Biology"） officially announced the establishment of a strategic partnership.

Both parties will focus on Benerhera's core pipeline BT-201 (the world’s first small-molecule topical formulation based on the Treg mechanism) and jointly advance its global research, registration, and commercialization in the animal health field. The product is based on a novel mechanism of core immunosuppression by regulatory T cells (Treg), originally discovered by Benerhera's founding team, marking the first time cutting-edge immune science has been translated into practical therapeutic applications. It provides an innovative solution for skin inflammatory diseases caused by autoimmune responses.

This collaboration not only represents a breakthrough in the industrial transformation of cutting-edge Treg immunology but also provides a disruptive treatment solution for autoimmune skin inflammatory diseases, marking China's original immunotherapy as a global leader in cross-species applications.

The 2025 Nobel Prize in Physiology or Medicine has been awarded to three scientists for their "discovery of regulatory T cells and their central role in peripheral immune tolerance," laying the foundation for understanding the pathogenesis of autoimmune diseases. Building on this, Benerhera's founding team has spent over a decade making a critical leap from basic research to applied transformation—systematically elucidating, for the first time, the molecular mechanism by which Treg cells exert immunosuppressive effects at the core stage of cell adhesion interactions, successfully identifying key signaling pathway regulatory targets.

This original discovery reveals that Treg cells can directly block the antigen presentation process of dendritic cells (DC cells, key antigen-presenting cells in the immune system) to effector T cells by enhancing specific adhesion with DC cells, thereby suppressing the initiation of inflammatory responses at the source. The elucidation of this mechanism provides entirely new theoretical support for the development of "precise targeting and localized regulation" immunotherapeutic drugs, fundamentally transforming the limitations of traditional immunotherapy reliant on "broad-spectrum suppression" or "single cytokine blockade."

BT-201 is developed based on the aforementioned original mechanism. By targeting and regulating key signaling pathways, it can induce the transformation of pro-inflammatory T cells in the body into Treg-like cells with immunomodulatory functions, achieving a phenotypic remodeling "from pathogenic cells to regulatory cells." Compared with traditional therapies, this mechanism can precisely restore local immune balance at the lesion site, avoiding the systemic decline in immune function caused by broad-spectrum immunosuppressants while addressing the limited efficacy of single-target drugs.

As the world's first small-molecule drug targeting the core immunosuppressive pathway of Tregs, BT-201 exhibits extremely high target specificity. Preclinical studies have shown that the drug can specifically accumulate at skin inflammatory lesions, exerting its therapeutic effects by modulating the local immune microenvironment without significantly affecting the body’s normal immune defense functions, ensuring treatment safety at the molecular level.

This collaboration is a key milestone for Benerhera in transforming its original scientific research achievements into industrial applications, and it also serves as an exemplary model of "original technology + commercialization capabilities" in China's animal health sector. Both parties will integrate core advantageous resources to accelerate the global industrialization process of BT-201.

The project sets up a ladder-style milestone covering key nodes such as preclinical research, clinical trials, global registration, and market launch. The total amount of the collaboration is expected to set a new historical high for technology licensing transactions in China's animal health sector, fully demonstrating the market's high recognition of the innovative value of the Treg mechanism.

Currently, the treatment of autoimmune skin diseases still relies on traditional drugs such as glucocorticoids, calcineurin inhibitors, and JAK inhibitors, which commonly present challenges like excessive immunosuppression, high drug resistance, frequent recurrence, and hepatorenal toxicity. The advent of BT-201 has completely transformed this landscape. Its core mechanism of "locally inducing Treg-like cells" achieves a dual effect of "immunosuppression + tissue repair," offering three major competitive advantages:

• Safety Breakthrough: Topical Application Avoids Systemic Side Effects, Significantly Reduces Liver and Kidney Burden;

• Efficacy Upgrade: Targeted induction of Treg-like cells enables long-term regulation of the local immune microenvironment, significantly reducing the recurrence rate of skin diseases;

• Human-Pet Co-Research Potential: Optimized based on the human Treg mechanism, with a scientific foundation for reversely promoting the upgrading of human immunotherapy drugs.

Industry analysis data shows that the global pet immunotherapy drug market is growing rapidly at a compound annual growth rate of 15.2%, and is expected to exceed $3 billion by 2030. Local immunotherapy drugs based on the Treg mechanism remain a blue ocean market. With its original mechanism and clinical advantages, BT-201 is expected to become a global benchmark product in this field.

Professor Yan Shi, founder of Benerhera (Ph.D. supervisor at Tsinghua University's Institute of Immunology, discoverer of the core immunosuppressive mechanism of Tregs)"We have spent over a decade to, for the first time from the perspective of cell mechanics, reveal the 'brake' mechanism of Treg in inflammatory responses. This is not only an extension of the Nobel Prize-winning research but also opens up a new direction for the treatment of autoimmune diseases. The translational application of BT-201 in animal health provides a replicable successful model for the industrialization of original basic research."

Liu Ailing, Dean of Reproductive Biology Research Institute"Treg cell technology represents a major breakthrough, precisely addressing the pain points of traditional pet immunotherapy. Animal experimental results show that BT-201 has demonstrated remarkable efficacy, enabling localized precision treatment and meeting the clinical need for both accuracy and safety. This indicates that the entire industry is poised to move from symptomatic suppression to a new phase of precision repair."

Professor Lin Jiahao from China Agricultural UniversityComment: "The traditional treatment of pet skin inflammation has long been limited by drug side effects and efficacy bottlenecks. The original mechanism of BT-201 provides a scientific solution to address hormone dependency and the toxic side effects of immunosuppressants. This collaboration achieves precise alignment between cutting-edge immunology science and animal clinical needs, marking an important milestone for the animal pharmaceuticals industry in advancing towards precision immune therapy."

Benerhera Chief Operating Officer Dr. Liu Feng"This collaboration marks a crucial leap for Benerhera from fundamental research to animal clinical trials. We firmly believe that BT-201 will redefine the treatment standards for immune diseases, offering safer and longer-lasting therapeutic options for global companion animals and livestock. It will also validate the universality of the Treg mechanism in cross-species applications, providing valuable data for subsequent human drug development. The channel advantages and global layout of Ringpu Biology in the animal health field are the core guarantees for this innovative technology to quickly benefit users worldwide."

Li Shoujun, Chairman of Ringpu BioStated: "For more than 20 years, Ringpu Bio has always been driven by innovation as its core driving force, continuously increasing R&D investment, closely monitoring breakthrough and disruptive technologies in the global biomedical field, and deeply cultivating the integration of industry, academia, and research for innovative development. BT-201 represents the top innovative direction we have long focused on. Ringpu Bio will comprehensively integrate its core advantages in R&D systems, manufacturing, and global channel layout to jointly accelerate the global commercialization process of BT-201 with Benerhera, making China-originated immunotherapy benefit pets worldwide. At the same time, through technological integration, we aim to lead the industry into a new era of precision immune treatment."

Benerhera (Shaoxing) Biotechnology Co., Ltd. was founded in December 2021 by Professor Yan Shi's team from the Institute of Immunology at Tsinghua University. It is a biopharmaceutical company focused on innovative Treg immunotherapy. The company addresses unmet clinical needs in autoimmune diseases, allergies, and inflammatory responses, and is committed to developing world-leading small molecule and cell therapy products. The core R&D team consists of immunology experts from top institutions such as Tsinghua University in China, the University of Toronto in Canada, the University of Calgary in Canada, and Leiden University in the Netherlands. The company has applied for more than 20 core patents and established a complete R&D system ranging from mechanistic research to product development.

Ringpu BioTech, founded in 1998 (Stock Code: 300119), is a leading enterprise in China's animal health industry and was listed on the ChiNext Board of the Shenzhen Stock Exchange in 2010. The company has over 20 subsidiaries and operates 105 large-scale production lines. Committed to innovation-driven development, Ringpu BioTech has achieved remarkable success in technology research and development, establishing platforms such as the "National Enterprise Technology Center," the "Key Laboratory of Biological Veterinary Drug Innovation of the Ministry of Agriculture," and the "Tianjin Key Laboratory of AI Drug Research and Development." To date, the company has obtained 118 New Veterinary Drug Registration Certificates and has been awarded the National Science and Technology Progress Award (Second Prize) twice. Its business spans chemical drugs, biological products, traditional Chinese veterinary medicine, active pharmaceutical ingredients, and functional feed additives, widely applied in pets, poultry, livestock, and aquaculture, providing comprehensive protection for animal health.